Speaker illustration

Doctor Peter Kolkhof

BAYER AG, R&D Pharmaceuticals, Wuppertal (Germany)

Member of:

European Society of Cardiology

Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?

Event: ESC Congress 2023

Topic: Aldosterone Antagonists

Session: Improving outcomes in heart failure: bench to bedside


Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

Event: ESC Congress 2021 - The Digital Experience

Topic: Target Organ Damage/Left Ventricular Hypertrophy

Session: Recent advances in diagnosis/treatment of hypertension


The best of two worlds: Vascular protection and decongestion without RAAS stimulation mediated by a novel dual acting V1a/V2 vasopressin receptor antagonist

Event: ESC Congress 2018

Topic: Pharmacotherapy

Session: Targeting reverse remodelling in heart failure


Get the right balance: a novel vasopressin receptor antagonist equally blocks human V1a and V2 receptors and inhibits the release of plasminogen activator inhibitor-1 from cardiomyocytes

Event: ESC Congress 2016

Topic: Pharmacologic therapy

Session: Novel pharmacological therapy in chronic heart failure


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb